Aspirin in Reducing Events in the Elderly

ASPREE is a double-blind, randomized, placebo-controlled primary prevention trial designed to assess whether daily active treatment of 100 mg enteric-coated aspirin will extend the duration of disability-free life in healthy participants aged 70 years and above except for Hispanic and African American minority groups in the U.S. where the minimum age of entry is 65 years.

The primary objective is to determine whether low-dose aspirin prolongs life, or life free of dementia, or life free of significant, persistent physical disability in the healthy elderly. Secondary objectives relate to the effects of low-dose aspirin on the key outcome areas of death, cardiovascular disease, dementia and cognitive decline, cancer, physical disability, depression and major bleeding episodes. Variables were collected annually through visits and for the purposes of retention telephone calls were scheduled at set points through the 7 years.

Types General population-based cohort
Participant Types No diagnosis
Countries Australia|USA
Genders Male and Female
Sample sizes 10,000 to 19,999
Ages 60 to 100
Brain related measures
Funtional rating Individual physiological|Individual psychological
Anthropometric Blood pressure|Height|Waist circumference|Weight
Physical Cardiovascular|Hearing and Vision
Biological samples Blood|Urine
Genotyping
Brain imaging Magnetic resonance imaging (MRI)
Brain banking
Lifestyle Alcohol|Dietary habits|Physical activity|Smoking
Socio-economic Education|Ethnic group|Family circumstances|Housing and accommodation|Income and finances|Informal support|Martial status|Occupation and employment|Unpaid care
Health service utilisation Formal health and social care service utilisation including private care
Institute names Monash University
Current Sample Sizes 10,000 to 19,999

age at recruitment > 65
last updated
recruitment period 2011
estimated current sample size number value
cohort acronym ASPREE
start date 2011
pi Professor Anne Murray, Professor John McNeil and Ms Brenda Kirpach
website http://www.aspree.org/
contact details USA:
ASPREE Project Manager, Brenda Kirpach
Berman Center for Outcomes & Clinical Research
701 Park Ave, Suite PPC4.440
Minneapolis, MN 55415

Australia:
ASPREE National Co-ordinating and Clinical Trial Centre,
Ground Floor, Burnet Building
89 Commercial Road, Melbourne 3004
abstract  ASPREE is a double-blind, randomized, placebo-controlled primary prevention trial. The primary objective is to determine whether low-dose aspirin prolongs life, or life free of dementia, or life free of significant, persistent physical disability in the healthy elderly. Variables will be collected annually for 7 years.
funders  USA and Australian Government
contact email [email protected]; [email protected]
PI email: [email protected]; [email protected]
contact phone number Tel: 612-873-6905
estimated current sample size
sample sizes 19,114